Business Context and Reporting Period
This is Synthetic Biologics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019—not a filing under the name Theriva Biologics stated in the request metadata. Synthetic Biologics was a clinical-stage microbiome therapeutics company, with programs including SYN-004, SYN-010 and SYN-020. The company reported no revenue for the quarter.
Financial Performance and Position
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Operating expenses | $3.572 million | $4.990 million |
| Operating loss | $3.572 million | $4.990 million |
| Net loss | $3.528 million | $2.326 million |
| Net loss attributable to common stockholders | $3.971 million | $2.375 million |
| Basic and diluted loss per share | $0.25 | $0.65 |
| Net cash used in operating activities | $4.224 million | $6.079 million |
Amounts are in U.S. dollars. The company had no revenue, so revenue-based margins are not meaningful. At March 31, 2019, cash and cash equivalents were $24.694 million, total current assets were $25.554 million, and current liabilities were $2.962 million. Total liabilities were $3.624 million; the filing reports no outstanding debt, while operating lease liabilities totaled $887,000. Accumulated deficit was $223.432 million and stockholders’ equity was $10.651 million. Cash declined $4.224 million from year-end 2018.
Changes Versus the Prior Comparable Period
- Operating expenses fell 28%: general and administrative costs decreased to $1.154 million from $1.620 million, and research and development costs to $2.418 million from $3.370 million. Management attributed the reductions mainly to lower stock-based compensation, restructuring-related savings, and reduced SYN-004 activity; increased SYN-020 manufacturing costs partly offset the R&D decrease.
- Net loss increased to $3.528 million from $2.326 million, largely because Q1 2018 included $2.655 million of noncash warrant fair-value income; Q1 2019 had no corresponding income. Common-stockholder loss also included preferred-stock dividends and a $398,000 Series B deemed dividend.
- Operating cash use improved to $4.224 million from $6.079 million.
- Weighted-average common shares rose to 15.657 million from 3.673 million, reflecting the company’s capital structure and share issuances/conversions; reported loss per share nevertheless decreased to $0.25 from $0.65.
- Adoption of lease accounting on January 1, 2019 added a right-of-use asset and lease liability; the prior-year comparison was not restated.
Outlook, Risks, and Other Notable Items
- Management said approximately $23 million of cash available in early May 2019 was expected to fund planned operations through at least the end of Q2 2020. The company cautioned that this would not fund later-stage or registrational trials.
- The proposed SYN-004 Phase 3 program for CDI prevention was expected to cost more than $80 million and was dependent on financing or a strategic partner. Management was considering a potentially smaller Phase 1/2 study in allogeneic HCT patients, targeted for the second half of 2019, subject to a research partner and approvals.
- SYN-010’s investigator-sponsored Phase 2b study had begun enrollment; topline results were anticipated in the second half of 2019. SYN-020’s anticipated IND filing was Q4 2019 and a Phase 1 trial was planned for Q1 2020.
- The company expected losses to continue and stated that additional capital might be needed. Equity financing could dilute shareholders; financing availability and terms were uncertain, and the company might have to delay or discontinue development activities. The ATM facility remained subject to restrictions, and no 2019 ATM sales were reported.
- Potential dilution is material: 18.916 million warrants were outstanding at quarter-end, mostly with a $1.38 exercise price, alongside convertible preferred stock. Actual dilution depends on exercise or conversion terms and market conditions.
- No material legal proceedings, off-balance-sheet arrangements, or material changes in internal controls were reported. Management concluded disclosure controls were effective as of March 31, 2019.
Important Facts for Investors to Verify
- Confirm the intended issuer: the supplied filing is for Synthetic Biologics, Inc., not Theriva Biologics.
- Track cash burn and financing capacity against management’s stated runway through Q2 2020, including ATM limitations and any partnership or capital-raising announcements.
- Verify clinical timelines and funding: SYN-010 Phase 2b results, the proposed SYN-004 HCT study, and SYN-020 IND and Phase 1 plans were forward-looking expectations, not guarantees.
- Assess potential dilution from outstanding warrants, Series B conversions, preferred dividends, and future equity financing.
- Distinguish operating performance from noncash warrant valuation effects and preferred-stock deemed dividends when evaluating period-to-period losses.